Investments
Novo Holdings Supports Reunion Neuroscience’s $103M Series A Funding for Pioneering Psychedelic Clinical Trials
Novo Holdings, Reunion Neuroscience, Series A funding, psychedelic clinical trials, mental health treatments, mental health innovation, venture capital, biotechnology, healthcare investments.
BridgeBio Secures $200 Million from Venture Capitalists to Propel Oncology Spinout Beyond KRAS Class
BridgeBio, venture capital, oncology, spinout, KRAS class, cancer treatment, biotechnology, drug development, investment, healthcare.
Enlaza Secures $100M for Groundbreaking Irreversible Protein Binding Technology
Enlaza, funding, investment, protein binding, irreversible, biotechnology, medical research, drug development, therapeutics.
Novartis Invests $180M in PeptiDream to Boost Radiopharmaceutical Development
Novartis, PeptiDream, radiopharmaceuticals, investment, drug development, partnership, targeted therapies, cancer treatment, radioactive isotopes.
Sanofi’s Strategic Acquisition of Principia Bears Fruit with Rilzabrutinib’s Phase III Success
Sanofi, Principia, acquisition, Rilzabrutinib, Phase III, clinical trial, success, strategic investment, pharmaceutical industry, biotechnology, drug development.
BMS Expands CAR-T Therapy Capabilities with Strategic $380 Million Investment in Cellares
BMS, Bristol Myers Squibb, Cellares, CAR-T therapy, cell therapy, cancer treatment, biotechnology, investment, capacity expansion, manufacturing, automation.
Pathios Secures $25M in Funding from BMS to Advance GPR65 Checkpoint Inhibitor Development
Pathios, Bristol-Myers Squibb (BMS), funding, GPR65, checkpoint inhibitor, cancer immunotherapy, drug development, biotechnology, investment.
Canaan Secures Additional $100M for Biopharma Fund and Welcomes Pfizer Veteran to Team
Canaan, Biopharma Fund, $100M Investment, Pfizer Veteran
Fujifilm Diosynth Announces $1.2B Expansion in North Carolina, Aiming to Employ 1,400
Fujifilm Diosynth Biotechnologies, $1.2 billion expansion, North Carolina, Holly Springs, 1/400 jobs, Biopharmaceutical manufacturing, End-to-end cell culture CDMO facility, Japanese investment
AstraZeneca Commits £650M Expansion for UK Vaccine Hub and Research Campus
AstraZeneca, £650 million investment, UK vaccine hub, Speke/ Liverpool, Renewable energy, Operationally net-zero facility, Research and Development (R&D) campus, Cambridge/ England, Job creation, Pandemic preparedness, Public health protection, Economic growth, Government support, Tax environment, Life sciences sector